Work

Immune checkpoint Inhibitor-Induced Autoimmune hemolytic anemia in endometrial cancer

Year: 2025

Type: article

Abstract: • Autoimmune hemolytic anemia AIHA) is a rare side effect of immune checkpoint inhibitor (ICI) therapy. • Management of ICI-induced AIHA involves ruling out other causes of anemia and immunosuppressive therapies. • The incidence of rare sequelae of ICI will increase with their increased importance in gynecologic oncology. • Multidisciplinary management will continue to be important for proper management of these rare sequlae. Immune checkpoint inhibitors (ICIs) have transformed management of advanced and recurrent endometrial carcinoma (EC). However, as their use increases, so too does the incidence of rare side effects related to their use. Here we describe a patient with stage IVB serous endometrial carcinoma who developed autoimmune hemolytic anemia (AIHA) following her second neoadjuvant cycle of carboplatin, paclitaxel, and dostarlimab. She was hospitalized, requiring multiple blood transfusions, a prolonged steroid course, and rituximab before stabilization of her anemia. Further cycles of chemotherapy without dostarlimab demonstrated good clinical response and did not reproduce AIHA. This case highlights the emerging multidisciplinary challenges that arise with the use of these novel targeted therapies. As the importance of these therapies increases in gynecologic oncologic management, it will be critical for providers to be able to diagnosis and manage their unique side effects.

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2025.101746

Authors: Michael Danziger, Isabella Hermantin, Fidel Valea, Joan Tymon-Rosario

Institutions: Northwell Health, Hofstra University, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $930